Anne Zanchi Delacrétaz

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


77 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 | 2006 | 2004 | 2003 | 2002 | 2000 | 1999 | 1998 | 1997 | 1995 | 1994 |
2024
 
The differential impact of a 6-versus 12-month pharmacist-led interprofessional medication adherence program on medication adherence in patients with diabetic kidney disease: the randomized PANDIA-IRIS study.
Bandiera C., Dotta-Celio J., Locatelli I., Nobre D., Wuerzner G., Pruijm M., Lamine F., Burnier M., Zanchi A., Schneider M.P., 2024. Frontiers in pharmacology, 15 p. 1294436. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_066459A6BF3A]
2023
 
Traduction et validation en langue française de l’instrument « Diabetes Knowledge Questionnaire » [Translation of the Diabetes Knowledge Questionnaire into French and its validation]
Helou N., Rapin M., Nobre D., Zanchi A., 2023/07/12. Recherche en soins infirmiers, 152 (1) pp. 60-76. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B3C07763A4BA]
 
Néphropathie diabétique : soutenir l’adhésion médicamenteuse de façon interprofessionnelle [Diabetic nephropathy: Interprofessional support of medication adherence]
Bandiera C., Duarte D., Dotta-Celio J., Zanchi A., Schneider M.P., 2023/05/31. Revue medicale suisse, 19 (829) pp. 1085-1089. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_4D4B823B11B7]
Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.
Zanchi A., Jehle A.W., Lamine F., Vogt B., Czerlau C., Bilz S., Seeger H., de Seigneux S., 2023/01/06. Swiss medical weekly, 153 p. 40004. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_761A8C74E5BC]
Blood pressure and vascular determinants of glomerular filtration rate decline in diabetic kidney disease.
Trucello L., Nobre D., Sabaratnam V., Bonny O., Wuerzner G., Burnier M., Fakhouri F., Pruijm M., Zanchi A., 2023. Frontiers in cardiovascular medicine, 10 p. 1230227. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_199BBB7CA1E4]
2022
Understanding reasons and factors for participation and non-participation to a medication adherence program for patients with diabetic kidney disease in Switzerland: a mixed methods study.
Bandiera C., Lam L., Locatelli I., Dotta-Celio J., Duarte D., Wuerzner G., Pruijm M., Zanchi A., Schneider M.P., 2022/09/27. Diabetology & metabolic syndrome, 14 (1) p. 140. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_679FC960BEF9]
En quoi la prise en charge de l’hypertendu diabétique est-elle différente? [How is the management of diabetic hypertensive patients different?]
Dufey Teso A., Lamine F., Zanchi A., Wuerzner G., 2022/09/14. Revue medicale suisse, 18 (795) pp. 1710-1716. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B533CB301DE1]
 
Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate.
Harmacek D., Pruijm M., Burnier M., Muller M.E., Ghajarzadeh-Wurzner A., Bonny O., Zanchi A., 2022/06. Journal of the American Society of Nephrology, 33 (6) pp. 1073-1075. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B566D465A0A5]
 
Metformin versus SGLT-2 inhibitors: how low can we go?
Pruijm M., Phan O., Zanchi A., 2022/05. Kidney international, 101 (5) pp. 874-877. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_465B201E6BF2]
Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.
Bandiera C., Pasquier J., Locatelli I., Niquille A., Wuerzner G., Dotta-Celio J., Hachfeld A., Wandeler G., Wagner A.D., Csajka C. et al., 2022. Patient preference and adherence, 16 pp. 2313-2320. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_813F43A545D0]
Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects.
Zanchi A., Pruijm M., Muller M.E., Ghajarzadeh-Wurzner A., Maillard M., Dufour N., Bonny O., Wuerzner G., Burnier M., 2022. Frontiers in cardiovascular medicine, 9 p. 854230. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6281EA6B3D3F]
2021
Antidiabétiques oraux et injectables pour le diabète de type 2 - Prise en charge multidisciplinaire du diabète : recommandations pour la pratique Clinique [Oral and injectable diabetes medications for type 2 diabetes - Multidisciplinary management of diabetes: Clinical practice guidelines]
Arditi C., Labud H., Roulet L., Zanchi A., Peytremann-Bridevaux I., 2021/06/23. Revue medicale suisse, 17 (744) p. 1237. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B92904824FF7]
SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review.
Lu H., Lu H., Kosinski C., Wojtusciszyn A., Zanchi A., Carron P.N., Müller M., Meyer P., Martin J., Muller O. et al., 2021/05/10. Journal of clinical medicine, 10 (9) p. 2036. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D78919AA8999]
 
Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS).
Bandiera C., Dotta-Celio J., Locatelli I., Nobre D., Wuerzner G., Pruijm M., Lamine F., Burnier M., Zanchi A., Schneider M.P., 2021/03/19. JMIR research protocols, 10 (3) pp. e25966. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_063BEE373E97]
Inhibiteurs du SGLT2 dans les néphropathies diabétiques et non diabétiques [SGLT2 inhibitors in diabetic and non-diabetic nephropathies]
Scheen M., Zanchi A., Martin P.Y., De Seigneux S., 2021/02/24. Revue medicale suisse, 17 (727) pp. 378-382. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_21FE0DE609F2]
2020
Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCGO-RCT).
Clair C., Augsburger A., Birrer P., Locatelli I., Schwarz J., Greub G., Zanchi A., Jacot-Sadowski I., Puder J.J., 2020/11/19. BMJ open, 10 (11) pp. e040117. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B8E00400B6EE]
A Multidisciplinary Approach for Improving Quality of Life and Self-Management in Diabetic Kidney Disease: A Crossover Study.
Helou N., Talhouedec D., Zumstein-Shaha M., Zanchi A., 2020/07/08. Journal of clinical medicine, 9 (7). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_91D0558C49D9]
Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
Zanchi A., Burnier M., Muller M.E., Ghajarzadeh-Wurzner A., Maillard M., Loncle N., Milani B., Dufour N., Bonny O., Pruijm M., 2020/07/07. Journal of the American Heart Association, 9 (13) pp. e016173. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D74B267E8EEE]
Adhésion thérapeutique et collaboration médecin-pharmacien. L’exemple du patient avec néphropathie diabétique [Medication adherence and physician-pharmacist collaboration. Focus on the patient with diabetic nephropathy]
Schneider M., Bandiera C., Dotta-Celio J., Zanchi A., 2020/06/10. Revue medicale suisse, 16 (697) pp. 1210-1213. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_28B47A354A6D]
Diabète post-transplantation rénale: le point de vue du diabétologue [Post-transplantation diabetes in kidney transplant: from the diabetologist point of view]
Pauchet A., Schwotzer N., Lamine F., Perrottet N., Zanchi A., Golshayan D., Wojtusciszyn A., 2020/06/10. Revue medicale suisse, 16 (697) pp. 1200-1205. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_77E6105192BB]
Diabète et infection à COVID-19 [Diabetes and COVID-19 infection]
Kosinski C., Zanchi A., Wojtusciszyn A., 2020/05/06. Revue medicale suisse, 16 (692) pp. 939-943. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_95589746FAF8]
2019
Health status and quality of life in patients with diabetes in Switzerland.
Arditi C., Zanchi A., Peytremann-Bridevaux I., 2019/06. Primary care diabetes, 13 (3) pp. 233-241. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D381D9B5F213]
 
Défis dans la prise en charge du diabète en hémodialyse chronique [Challenges in managing diabetes in chronic hemodialysis]
Lamine F., Chtioui H., Schwotzer N., Pruijm M., Nobre D., Phan O., Ammor N., Andrey M., Grangier-Bernard P., Zanchi A., 2019/05/29. Revue medicale suisse, 15 (653) pp. 1132-1139. Peer-reviewed.
[Pmid][serval:BIB_3C34A5DC9916]
Néphropathie diabétique - Prise en charge multidisciplinaire du diabète : recommandations pour la pratique clinique
Arditi C., Zanchi A., Hagon-Traub I., Burnand B., 2019/04/17. Revue medicale suisse, 15 (647) p. 841. Peer-reviewed.
[URN][serval:BIB_2152D3CBC6EB]
 
Acute hyperglycemia increases renal tissue oxygenation as measured by BOLD-MRI in healthy overweight volunteers.
Vakilzadeh N., Zanchi A., Milani B., Ledoux J.B., Braconnier P., Burnier M., Pruijm M., 2019/04. Diabetes research and clinical practice, 150 pp. 138-143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FDDB398D3EE6]
2018
 
Erratum to: Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis.
Helou N., Dwyer A., Shaha M., Zanchi A., 2018/09..
[DOI][Pmid][serval:BIB_45DAEE712B0F]
Antidiabétiques oraux et injectablespour le diabète de type 2 - Prise en charge multidisciplinaire du diabète : recommandations pour la pratique clinique []
Arditi C., Zanchi A., Hagon-Traub I., Burnand B., 2018/08/08. Revue medicale suisse, 14 (614) p. 1425. Peer-reviewed.
[URN][Pmid][serval:BIB_3E77B028A3A9]
Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol.
Muller M.E., Pruijm M., Bonny O., Burnier M., Zanchi A., 2018/06. Advances in therapy, 35 (6) pp. 875-885. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5B126CD40DD9]
2017
Changing trends in end-stage renal disease patients with diabetes.
Lu Y., Stamm C., Nobre D., Pruijm M., Teta D., Cherpillod A., Halabi G., Phan O., Fumeaux Z., Bullani R. et al., 2017/07/11. Swiss medical weekly, 147 pp. w14458. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03D3BBAF84B1]
Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
Corcillo A., Pivin E., Lalubin F., Pitteloud N., Burnier M., Zanchi A., 2017/07/11. Swiss medical weekly, 147 pp. w14459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DBE1BC845497]
 
Autosurveillance de la glycémie lors du diabète Prise en charge multidisciplinaire du diabète :recommandations pour la pratique clinique
Rosselet P., Zanchi A., Hagon-Traub I., Burnand B., 2017/03/22. Revue medicale suisse, 13 (555) p. 665. Peer-reviewed.
[Pmid][serval:BIB_C54248B163D9]
 
Diabète de type 2 et néphropathie
Zanchi Anne, 2017/01. La Gazette Médicale info@gériatrie pp. 22-24.
[serval:BIB_0C3AB2AB70F1]
 
Insuffisance rénale et diabète: les précautions à prendre.
Zanchi Anne, Cherpillod Anne, Pitteloud Nelly, Burnier Michel, Pruijm Menno, 2017. Forum Médical Suisse, 14 (6) pp. 100-104. Peer-reviewed.
[serval:BIB_E61F65A35BEE]
2016
 
Recommandations de pratique clinique concernant les soins aux personnes vivant avec un diabète
Rosselet P., Zanchi A., Hagon-Traub I., Burnand B., 2016/09/21. Revue medicale suisse, 12 (531) pp. 1584-1585. Peer-reviewed.
[Pmid][serval:BIB_DB1C9B1B8DBA]
The impact of a multidisciplinary self-care management program on quality of life, self-care, adherence to anti-hypertensive therapy, glycemic control, and renal function in diabetic kidney disease: A Cross-over Study Protocol.
Helou N., Talhouedec D., Shaha M., Zanchi A., 2016/07/19. BMC nephrology, 17 (1) p. 88. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DDC0D2B4F4B4]
 
Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis.
Helou N., Dwyer A., Shaha M., Zanchi A., 2016/07. JBI database of systematic reviews and implementation reports, 14 (7) pp. 169-207. Peer-reviewed.
[DOI][Pmid][serval:BIB_27ED14B8BDFC]
Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs.
Lamine F., Lalubin F., Pitteloud N., Burnier M., Zanchi A., 2016. Swiss Medical Weekly, 146 pp. w14282. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2C70F77224E2]
2015
 
DIABÈTE INAUGURAL [Inaugural diabetes]
Abetel G., Tran C., Zanchi A., 2015/12/09. Revue medicale suisse, 11 (498) pp. 2346-2348. Peer-reviewed.
[Pmid][serval:BIB_38CBCD5C140F]
 
Les inhibiteurs du cotransporteur SGLT2 comme nouveau traitement du diabète: aspects rénaux [Renal aspects of sodium glucose cotransporter 2 inhibitors]
Beaud F., Pruijm M., Humbert A., Burnier M., Zanchi A., 2015/02/25. Revue medicale suisse, 11 (463) pp. 488-492. Peer-reviewed.
[Pmid][serval:BIB_8417778860E6]
2014
Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study.
Zanchi A., Tappy L., Lê K.A., Bortolotti M., Theumann N., Halabi G., Gauthier T., Mathieu C., Tremblay S., Bertrand P.C. et al., 2014/10. Plos One, 9 (10) pp. e109134. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1D97934B1629]
 
Antidiabétiques et insuffisance rénale
Lamine Faiza, Philippe Jacques, Zanchi Anne, 2014/09. MCED, 72 pp. 21-27.
[serval:BIB_A5941B08216C]
Long-term low-dose ketoconazole treatment in bilateral macronodular adrenal hyperplasia
Comte-Perret S., Zanchi A., Gomez F., 2014. Endocrinology, Diabetes and Metabolism Case Reports, 2014 p. 140083. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_78949E9CE64E]
2013
 
Blockade of the renin-angiotensin system and renal tissue oxygenation as measured with BOLD-MRI in patients with type 2 diabetes.
Pruijm M., Hofmann L., Zanchi A., Maillard M., Forni V., Muller M.E., Wuerzner G., Vogt B., Stuber M., Burnier M., 2013. Diabetes Research and Clinical Practice, 99 (2) pp. 136-144. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB1FB150E41F]
2012
Antidiabetic drugs and kidney disease - Recommendations of the Swiss Society for Endocrinology and Diabetology.
Zanchi A., Lehmann R., Philippe J., 2012. Swiss Medical Weekly, 142 pp. w13629.
[URN][DOI][WoS][Pmid][serval:BIB_0B982F37FE27]
2011
 
Diabète et insuffisance rénate terminate. Evolution en huit ans dans le canton de Vaud [Diabetes and end stage renal disease. Eight year progression in the Canton de Vaud, Switzerland].
Stamm C., Burnier M., Zanchi A., 2011. Revue Médicale Suisse, 7 (284) pp. 495-499.
[Pmid][serval:BIB_86595ACCB86C]
 
Effects of pioglitazone on renal calcium excretion.
Zanchi A., Pechère-Bertschi A., Burnier M., Bonny O., 2011. Journal of Clinical Endocrinology and Metabolism, 96 (9) pp. E1482-E1485.
[DOI][WoS][Pmid][serval:BIB_E58C3CDE505B]
2010
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals.
Zanchi A., Maillard M., Jornayvaz F.R., Vinciguerra M., Deleaval P., Nussberger J., Burnier M., Pechere-Bertschi A., 2010. Diabetologia, 53 (8) pp. 1568-1575.
[URN][DOI][WoS][Pmid][serval:BIB_2DCD23BF24A5]
 
Evidence against a direct role of klotho in insulin resistance.
Lorenzi Olivier, Veyrat-Durebex Christelle, Wollheim Claes B., Villemin Pascal, Rohner-Jeanrenaud Francoise, Zanchi Anne, Vischer Ulrich M., 2010. Pflügers Archiv : European Journal of Physiology, 459 (3) pp. 465-473. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0AA9B4D1F08B]
 
Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.
Aubert Gregory, Burnier Michel, Dulloo Abdul, Perregaux Christine, Mazzolai Lucia, Pralong Francois, Zanchi Anne, 2010. Metabolism: Clinical and Experimental, 59 (1) pp. 25-32. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30E656105251]
2008
 
Activation of electrical triggers of atrial fibrillation in hyperthyroidism.
Wustmann K., Kucera J.P., Zanchi A., Burow A., Stuber T., Chappuis B., Diem P., Delacrétaz E., 2008. Journal of Clinical Endocrinology and Metabolism, 93 (6) pp. 2104-2108. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E4314ED33B38]
 
Sodium balance in the metabolic syndrome and diabetes
Zanchi A, 2008. dans Burnier Michel (eds.) Sodium in health and disease, Informa Healthcare.
[serval:BIB_FAB2359C91A8]
2007
 
Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties
Zanchi A., Dulloo A. G., Perregaux C., Montani J. P., Burnier M., 2007/07. American Journal of Physiology - Endocrinology and Metabolism, 293 (1) pp. E91-5. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_102CD43DB74E]
 
Diabète et insuffisance cardiaque chez la personne agée
Vischer U, Zanchi A., 2007/03. Gériatrie Pratique pp. 16-19.
[serval:BIB_70313A89A4D8]
 
Insuffisance renale chronique et medicaments antidiabetiques. [Chronic kidney disease and antidiabetic treatment]
Berwert L., Teta D., Zanchi A., 2007/03. Revue Médicale Suisse, 3 (101) pp. 598-604.
[Pmid][serval:BIB_AF44B6D9AFE2]
2006
 
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes
Burnier M., Zanchi A., 2006/01. Journal of Hypertension, 24 (1) pp. 11-25. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D29795B7F19E]
 
The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.
Zanchi A., Perregaux C., Maillard M., Cefai D., Nussberger J., Burnier M., 2006. American journal of physiology. Endocrinology and metabolism, 291 (6) pp. E1228-34. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_95BC823E0AC8]
2004
 
Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.
Zanchi A., Chiolero A., Maillard M., Nussberger J., Brunner H.R., Burnier M., 2004. Journal of Clinical Endocrinology and Metabolism, 89 (3) pp. 1140-1145. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_48EF40A166F5]
 
Faut-il bloquer le système rénine-angiotensine pour prévenir le diabète de type 2 ?
Zanchi A., Burnier M., 2004. Médecine et Hygiène, 62 (2495) pp. 1717-1720.
[serval:BIB_B0071E965E2B]
2003
 
Neueste Studien zu diabetischer nephropathie und hypertonie. Welche medicamente machen das rennen
Zanchi A., Burnier M., 2003. Cardiovasc, 4 (35-39).
[serval:BIB_CD7297F93E13]
 
Recent clinical trials with omapatrilat: new developments.
Zanchi A., Maillard M., Burnier M., 2003. Current hypertension reports, 5 (4) pp. 346-52. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_29842]
2002
 
Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity
Szabo C., Zanchi A., Komjati K., Pacher P., Krolewski A. S., Quist W. C., LoGerfo F. W., Horton E. S., Veves A., 2002/11. Circulation, 106 (21) pp. 2680-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D7A8E6D8DB71]
2000
 
Testing mode of inheritance of a candidate mutation at a quantitative trait locus
Rabinowitz D., Zanchi A., Schaumberg D., Krolewski A., 2000/06. Human Heredity, 50 (3) pp. 184-8. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F234259861AC]
 
Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism
Zanchi A., Moczulski D. K., Hanna L. S., Wantman M., Warram J. H., Krolewski A. S., 2000/02. Kidney International, 57 (2) pp. 405-13. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F08A3369BB5]
1999
 
Aortic connexin43 is decreased during hypertension induced by inhibition of nitric oxide synthase
Haefliger J. A., Meda P., Formenton A., Wiesel P., Zanchi A., Brunner H. R., Nicod P., Hayoz D., 1999/07. Arteriosclerosis, Thrombosis, and Vascular Biology, 19 (7) pp. 1615-22.
[WoS][Pmid][serval:BIB_4AD83075B745]
1998
 
Differences in the mechanical properties of the rat carotid artery in vivo, in situ, and in vitro
Zanchi A., Stergiopulos N., Brunner H. R., Hayoz D., 1998/07. Hypertension, 32 (1) pp. 180-5.
[WoS][Pmid][serval:BIB_5EAD60DC9CB6]
1997
 
Age-related changes of the mechanical properties of the carotid artery in spontaneously hypertensive rats
Zanchi A., Brunner H. R., Hayoz D., 1997/12. Journal of Hypertension, 15 (12 Pt 1) pp. 1415-22.
[DOI][WoS][Pmid][serval:BIB_5E03B11AD032]
 
Time course changes of the mechanical properties of the carotid artery in renal hypertensive rats.
Zanchi A., Wiesel P., Aubert J.F., Brunner H.R., Hayoz D., 1997. Hypertension, 29 (5) pp. 1199-1203. Peer-reviewed.
[WoS][Pmid][serval:BIB_85FF4D0F2F3E]
1995
 
Endothelial function of the mesenteric arteriole and mechanical behaviour of the carotid artery in rats with insulin resistance and hypercholesterolaemia.
Zanchi A., Delacrétaz E., Taleb V., Gaillard R., Jeanrenaud B., Brunner H.R., Waeber B., 1995/12. Journal of hypertension, 13 (12 Pt 1) pp. 1463-1470. Peer-reviewed.
[WoS][Pmid][serval:BIB_62D1416BE883]
 
Renal haemodynamic and protective effects of calcium antagonists in hypertension
Zanchi A., Brunner H. R., Waeber B., Burnier M., 1995/12. Journal of Hypertension, 13 (12 Pt 1) pp. 1363-75. Peer-reviewed.
[Pmid][serval:BIB_901C61C54A2F]
Vascular acetylcholine response during chronic NO synthase inhibition: in vivo versus in vitro.
Zanchi A., Aubert J.F., Brunner H.R., Waeber B., 1995/07. Cardiovascular Research, 30 (1) pp. 122-129. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B125B40999F2]
 
Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system.
Zanchi A., Schaad N.C., Osterheld M.C., Grouzmann E., Nussberger J., Brunner H.R., Waeber B., 1995/06. American Journal of Physiology. Heart and Circulatory Physiology, 268 (6 Pt 2) pp. H2267-H2273.
[Pmid][serval:BIB_A69E70D80300]
 
Chronic nitric oxide synthase inhibition and carotid artery distensibility in renal hypertensive rats.
Delacrétaz E., Zanchi A., Nussberger J., Hayoz D., Aubert J.F., Brunner H.R., Waeber B., 1995. Hypertension, 26 (2) pp. 332-6. Peer-reviewed.
[WoS][Pmid][serval:BIB_4563109450B9]
 
Le diagnostic et le traitement de l'hypertension artérielle
Waeber B., Burnier M., Zanchi A., Brunner HR, 1995. Médecine et Hygiène, 53 (2066) pp. 743-745.
[serval:BIB_EE44ECB74797]
 
Le traitement de l'hypertension artérielle : La place d'une apprche non parmacologique
Weber R., Zanchi A., Brunner H.R., Waeber B., 1995. Médecine et Hygiène, 53 (2054) pp. 87-92.
[serval:BIB_F45F7D1FD8D1]
1994
 
Anaphylactoid purpura like vasculitis following fibrinolytic therapy: role of the immune response to streptokinase
Lantin J. P., Gattesco S., Duclos A., Zanchi A., Schaller M. D., Pecoud A., Aubert V., 1994/08. Clinical and Experimental Rheumatology, 12 (4) pp. 429-33.
[WoS][Pmid][serval:BIB_A375063091C7]
 
Angiotensin-converting enzyme inhibition by hydroxamic zinc-binding idrapril in humans.
Zanchi A., Nussberger J., Criscuoli M., Capone P., Brunner H.R., 1994. Journal of cardiovascular pharmacology, 24 (2) pp. 317-22. Peer-reviewed.
[WoS][Pmid][serval:BIB_13167B628C6D]
 
Is antihypertensive therapy expected to be different in postmenopausal women?
Springer-Verlag Berlin Heidelberg (eds.)Zanchi A, Brunner HR, 1994..
[serval:BIB_A8D902FC5331]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University